INDIANAPOLIS, May 18, 2016 /PRNewswire/ -- Several studies will underscore the strength of Eli Lilly and Company's (NYSE: LLY) diverse clinical cancer pipeline and portfolio during the 52 nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 3 - 7, 2016. Presentations include new data on abemaciclib, a CDK 4 and ... Jun 01, 2020 · Shots: The CodeBreaK 100 development program evaluates AMG 510 (proposed INN sotorasib, qd) in heavily pretreated patients with a range of KRAS G12C-mutant solid tumors. Eligible patients were heavily pretreated with at least 2L+ treatment and were enrolled four dose cohorts: 180 mg/360 mg/720 mg/960 mg This Phase 1 dose-escalation study evaluated 42 heavily pretreated […]
AMG-510: This year, results were presented on AMG-510 which showed a high response rate in both lung and colorectal cancers. AMG-510 targets a KRAS mutation also known as KRAS G12C, which occurs in approximately 3-5% of colon and rectal cancers.